title: Late outcome of 304 consecutive patients with multiple gland enlargement in primary hyperparathyroidism treated by conservative surgery.
abstract: The aim of this study was to assess the late outcome of patients with primary hyperparathyroidism and multiple gland enlargement (MGE) treated by conservative surgery. MGE in primary hyperparathyroidism is the presence of two or more enlarged glands weighing more than 50 mg. Conservative surgery consists in resecting the grossly enlarged glands without biopsying the normal glands. Some authors have suggested that this approach overlooks minute hyperplasia, leading to late recurrences of hyperparathyroidism; conversely, it may result in the unnecessary resection of grossly enlarged, but not hyperfunctioning, glands. Altogether 1231 patients were operated on for primary hyperparathyroidism between 1966 and 1995. Of these patients, 304 (24.9%) had MGE, including 42 cases of multiple endocrine neoplasia (MEN), 12 familial cases, and 250 seemingly sporadic cases. Two, three, or four glands (or more) were involved in 61.8%, 21.4%, and 16.4% of cases, respectively. During the early postoperative period one patient died and ten were reoperated for persistent hypercalcemia. The pathologic diagnoses were double adenomas (13.5%), hyperplasia (35.8%), association of the two (39.8%), and a normal second gland (10.8%) on light microscopy findings. None of the 30 deaths that occurred during follow-up was related to hyperparathyroidism. Altogether 190 patients (79%) were available for follow-up (average 89.3 months): 90% were normocalcemic, 4.7% hypocalcemic, and 5.2% hypercalcemic. A late iPTH assay was done in 147. PTH was appropriate to the serum calcium level in 84.3% and appropriate to normal calcemia in 91.6% of 132 cases. Conservative surgery is thus an acceptable treatment for MGE in patients with hyperparathyroidism. Few late recurrences occur, for which there are no individual predictive criteria.
authors.affiliation: Department of General and Endocrine Surgery, Hospital Huriez, CHU, Lille, France.
authors.forename: C
authors.initials: C
authors.lastname: Proye
authors.forename: B
authors.initials: B
authors.lastname: Carnaille
authors.forename: J L
authors.initials: JL
authors.lastname: Quievreux
authors.forename: F
authors.initials: F
authors.lastname: Combemale
authors.forename: C
authors.initials: C
authors.lastname: Oudar
authors.forename: M
authors.initials: M
authors.lastname: Lecomte-Houcke
mesh_terms: D000236:Adenoma / Q000473:pathology; D006801:Humans; D006961:Hyperparathyroidism / Q000473:pathology* / Q000601:surgery*; D018761:Multiple Endocrine Neoplasia Type 1 / Q000473:pathology; D018813:Multiple Endocrine Neoplasia Type 2a / Q000473:pathology; D010282:Parathyroid Neoplasms / Q000473:pathology; D016896:Treatment Outcome